Similar companies
Income Statement (USD)
Q3 '24 | QoQ | |
---|---|---|
Revenue | 3.1M | 27.2% |
Gross Profit | -170,000 | 65.3% |
Cost of Revenue | 12M | 6.7% |
Operating expense | 7.8M | 5.7% |
Net Income | -6.6M | 7.1% |
EBITDA | -7M | 1.2% |
Balance Sheet (USD)
Q3 '24 | QoQ | |
---|---|---|
Total Assets | 92M | 2% |
Total Liabilities | 54M | 8.2% |
Total Equity | 38M | 13.5% |
Shares Outstanding | 19M | 0% |
Cash Flow (USD)
Q3 '24 | QoQ | |
---|---|---|
Cash from operations | -4M | 16.4% |
Cash from investing | -97,000 | 178.2% |
Cash from financing | 2.9M | 46.3% |
EPS
Financial Highlights for ProPhase Labs in Q3 '24
ProPhase Labs reported a revenue of 3.1M, which is a 27.2% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at -170,000, marking a 65.3% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 12M, a 6.7% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 7.8M, showing a 5.7% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -6.6M, showing a -7.1% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -7M, showing a 1.2% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
ProPhase Labs faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies.